NFE2L2 and Hodgkins lymphoma: (101) found that in Hodgkin lymphoma cell lines, the proteasome inhibitor Ixazomib (25–75 nM) transiently inhibits proteasome activity, but subsequent functional recovery occurs due to NFE2L2 (NRF2)-dependent upregulation of proteasome gene expression.